Global Tetraspecific Antibodies Clinical Trials & Market Report 2024: Pioneering the Future of Cancer Treatment, Shift Towards Tetraspecific Antibodies Amidst Drug Resistance Challenges
31 mai 2024 04h48 HE
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Global Tetraspecific Antibodies Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's...
Dyadic to Attend Industry Events in June
30 mai 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
28 mai 2024 07h35 HE
|
Numab Therapeutics AG
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD
Fc and Glycoengineered Antibodies Research 2024: Market Experiences Over 30% Growth in Collaborations in Past Two Years, Fueled by Strategic Partnerships - Long-term Forecasts to 2035
22 mai 2024 04h47 HE
|
Research and Markets
Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Fc and Glycoengineered Antibodies Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Engineering, Type of Therapy,...
BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten
21 mai 2024 06h45 HE
|
BioNTech SE
MAINZ, Deutschland, 21. Mai 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 31....
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
21 mai 2024 06h45 HE
|
BioNTech SE
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at...
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
14 mai 2024 16h00 HE
|
Dyadic International, Inc.
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant...
Antibody Discovery Market Analysis 2018-2023 and Outlook 2024-2033 Featuring Danaher, Eurofins Scientific, Sartorius, Charles River Labs, and Bruker
10 mai 2024 09h07 HE
|
Research and Markets
Dublin, May 10, 2024 (GLOBE NEWSWIRE) -- The "Antibody Discovery Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global antibody discovery market has grown...
Dyadic to Attend Industry and Investor Events in May
08 mai 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Monoclonal Antibody Collaboration, Development, Research and Licensing Deals Analysis Report 2024 with Directory of 970+ Agreements Signed Since 2014
07 mai 2024 06h55 HE
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Monoclonal Antibody...